Igamad (Human Anti-D Immunoglobulin)

Human Anti-D Immunoglobulin binds to RhD‑positive red blood cells, masking the D antigen. This prevents the maternal immune system from recognizing the antigen and forming anti‑D antibodies, thereby averting sensitization and subsequent hemolytic disease in future pregnancies.

The dosage of Igamad is determined by the prescribing clinician based on the patient’s Rh status, gestational age, and clinical scenario. Healthcare providers calculate the appropriate volume to achieve effective prophylaxis.

Igamad is specifically indicated for use in pregnant women who are Rh‑negative. It is considered safe when administered according to clinical guidelines. Limited data are available for breastfeeding, and the decision should be made by the prescriber after evaluating the benefit‑risk profile.

To order Igamad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Igamad is a human anti‑D immunoglobulin similar in composition to other licensed anti‑D preparations. Differences may lie in manufacturing processes, concentration, and regulatory approvals. Clinical efficacy and safety are comparable when used according to guidelines.

Igamad should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain product stability.

Igamad is supplied as a sterile solution for injection and is administered intramuscularly. The injection is typically given in the deltoid or gluteal muscle by a qualified healthcare professional following aseptic technique.

Serious risks include severe allergic reactions such as anaphylaxis, acute hemolysis, renal impairment, and rare thromboembolic events. Patients should be monitored closely during and after administration for any signs of these adverse reactions.

Igamad should not be given to individuals with known hypersensitivity to human immunoglobulin preparations, IgA deficiency with anti‑IgA antibodies, or those who have previously experienced severe reactions to anti‑D immunoglobulin. Clinical judgment is required for all contraindications.